Elizabeth Plimack, MD, MS, FASCO
Elizabeth Plimack, MD, MS, FASCO, is the Deputy Director of Fox Chase Cancer Center.
Articles by Elizabeth Plimack, MD, MS, FASCO
The panel shares the NIAGARA findings and results from RETAIN-2 on dose-dense MVAC for bladder preservation.
The panel covers 2L treatment options for mUC post-EV/pembro, with emphasis on platinum-based chemo and targeted therapy.
The panel debates patient selection, alternative regimens, and the balance between escalation and de-escalation strategies.
The panel weighs the impact of long-term survival data from the EV-302 trial, with significant improvements in OS.
Dr. Plimack provides an update on the SWOG S1314 trial for MIBC, including four genes predictive of pT0 disease after NAC.
The panel shares their outlook on the near future for renal cell carcinoma research, treatment, and care.
The panel discussed important takeaways from RCC studies presented at ASCO GU.
The panel shifts to focus on the current state of non-clear cell kidney cancer.
Dr. Voss compares IO/IO and TKI/IO treatment options, as well as toxicity considerations.
Dr. McDermott advocates for immune therapy in frontline RCC care.
Dr. Plimack shared her approach to frontline clear cell kidney cancer treatment selection.
Dr. Plimack comments on long-term survival data from nivolumab/ipilimumab in the CheckMate 214 study as well as other data.
Dr. Plimack provides a summary of her presentation at the SUO Annual Meeting on the progress of ADCs in UC research.
Drs. Rini and Plimack discuss the "negative" findings from CONTACT-03.
Drs. Rini and Plimack discuss "impressive" non-clear cell RCC data.
Drs. Rini and Plimack discuss the CLEAR and KEYNOTE-426 RCC updates.
Dr. Plimack discusses the results of her phase 2 study on hypomethylating agents, and gives a preview of research to come.
Elizabeth Plimack, MD, MS, provides an overview of a recent phase 2 trial of guadecitabine plus atezolizumab for mUC.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.